These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2490824)

  • 21. The effect of blood pressure reduction on end stage renal disease.
    Jamerson K
    Am J Hypertens; 1996 Aug; 9(8):60s-64s. PubMed ID: 8862239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertension and kidney disease: a deadly connection.
    Barri YM
    Curr Hypertens Rep; 2008 Feb; 10(1):39-45. PubMed ID: 18367025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal consequences of arterial hypertension.
    Ruilope LM; Alcázar JM; Rodicio JL
    J Hypertens Suppl; 1992 Dec; 10(7):S85-90. PubMed ID: 1291661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertension in chronic dialysis patients: pathophysiology, monitoring, and treatment.
    Morse SA; Dang A; Thakur V; Zhang R; Reisin E
    Am J Med Sci; 2003 Apr; 325(4):194-201. PubMed ID: 12695724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.
    Hsu CY; McCulloch CE; Darbinian J; Go AS; Iribarren C
    Arch Intern Med; 2005 Apr; 165(8):923-8. PubMed ID: 15851645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ambulatory blood pressure during diseases of the kidney.
    Redon J; Oliver V; Zaragoza MD; Galindo MJ
    Blood Press Monit; 1999 Oct; 4(5):267-74. PubMed ID: 10547649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.
    Sim JJ; Bhandari SK; Shi J; Reynolds K; Calhoun DA; Kalantar-Zadeh K; Jacobsen SJ
    Kidney Int; 2015 Sep; 88(3):622-32. PubMed ID: 25945406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant hypertension: a preventable emergency.
    van der Merwe W; van der Merwe V
    N Z Med J; 2013 Aug; 126(1380):39-45. PubMed ID: 24126748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which antihypertensive drugs are the most nephroprotective and why?
    Cravedi P; Ruggenenti P; Remuzzi G
    Expert Opin Pharmacother; 2010 Nov; 11(16):2651-63. PubMed ID: 20977400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. End-stage renal disease: a southern epidemic.
    Moore MA
    South Med J; 1994 Oct; 87(10):1013-7. PubMed ID: 7939913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease.
    He J; Whelton PK
    J Hypertens Suppl; 1999 Jun; 17(2):S7-13. PubMed ID: 10465061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does essential hypertension cause end-stage renal disease?
    Weisstuch JM; Dworkin LD
    Kidney Int Suppl; 1992 May; 36():S33-7. PubMed ID: 1614065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease.
    Ku E; Glidden DV; Johansen KL; Sarnak M; Tighiouart H; Grimes B; Hsu CY
    Kidney Int; 2015 May; 87(5):1055-60. PubMed ID: 25493952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat?
    Rosansky SJ
    Blood Purif; 1996; 14(4):315-20. PubMed ID: 8873957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Renal insufficiency in arterial hypertension in black Africa].
    Lengani A; Laville M; Serme D; Fauvel JP; Ouandaogo BJ; Zech P
    Presse Med; 1994 Apr 30-May 7; 23(17):788-92. PubMed ID: 8078835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Racial differences in trends of end-stage renal disease, by primary diagnosis--United States, 1994-2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(11):253-6. PubMed ID: 17380108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension control and antihypertensive therapy in patients with chronic kidney disease.
    Unni S; White K; Goodman M; Ye X; Mavros P; Bash LD; Brixner D
    Am J Hypertens; 2015 Jun; 28(6):814-22. PubMed ID: 25421796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.